308 related articles for article (PubMed ID: 25170194)
21. Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma.
Occhipinti V; Farina L; Viganò M; Capecchi M; Labanca S; Fanetti I; Corradini P; Rumi M
Dig Liver Dis; 2019 May; 51(5):719-723. PubMed ID: 30502232
[TBL] [Abstract][Full Text] [Related]
22. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
Huang H; Li X; Zhu J; Ye S; Zhang H; Wang W; Wu X; Peng J; Xu B; Lin Y; Cao Y; Li H; Lin S; Liu Q; Lin T
JAMA; 2014 Dec; 312(23):2521-30. PubMed ID: 25514302
[TBL] [Abstract][Full Text] [Related]
23. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
Yamauchi N; Maruyama D; Choi I; Atsuta Y; Sakai R; Miyashita K; Moriuchi Y; Tsujimura H; Kubota N; Yamamoto G; Igarashi T; Izutsu K; Yoshida S; Kojima K; Uchida T; Inoue Y; Tsukamoto N; Ohtsuka E; Suzuki S; Inaguma Y; Ichikawa S; Gomyo H; Ushijima Y; Nosaka K; Kurata M; Tanaka Y; Ueda R; Mizokami M; Kusumoto S
Cancer Sci; 2021 May; 112(5):1943-1954. PubMed ID: 33576088
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: a single center experience.
Nishikawa H; Tsudo M; Osaki Y
Oncol Rep; 2012 Sep; 28(3):835-40. PubMed ID: 22736295
[TBL] [Abstract][Full Text] [Related]
25. Does the presence of hepatitis virus B and C influence the evolution of diffuse large B-cell lymphoma?
Rubio J; Franco F; Sánchez A; Cantos B; Méndez M; Calvo V; Maximiano C; Perez D; Millán I; Sánchez-Beato M; Provencio M
Leuk Lymphoma; 2015 Jun; 56(6):1686-90. PubMed ID: 25219591
[TBL] [Abstract][Full Text] [Related]
26. Splenic large B-cell lymphoma in patients with hepatitis C virus infection.
Takeshita M; Sakai H; Okamura S; Oshiro Y; Higaki K; Nakashima O; Uike N; Yamamoto I; Kinjo M; Matsubara F
Hum Pathol; 2005 Aug; 36(8):878-85. PubMed ID: 16112004
[TBL] [Abstract][Full Text] [Related]
27. Hepatitis C virus infection prevalence and liver dysfunction in a cohort of B-cell non-Hodgkin's lymphoma patients treated with immunochemotherapy.
Nosotti L; D'Andrea M; Pitidis A; Pimpinelli F; Dessanti ML; Pisani F; Vignally P; Petti MC
Scand J Infect Dis; 2012 Jan; 44(1):70-3. PubMed ID: 21905952
[TBL] [Abstract][Full Text] [Related]
28. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy.
Visco C; Arcaini L; Brusamolino E; Burcheri S; Ambrosetti A; Merli M; Bonoldi E; Chilosi M; Viglio A; Lazzarino M; Pizzolo G; Rodeghiero F
Ann Oncol; 2006 Sep; 17(9):1434-40. PubMed ID: 16766591
[TBL] [Abstract][Full Text] [Related]
29. [Comparative analysis of liver function in HBsAg-/HBcAb+ patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP regimens].
Huang YH; He XH; Qin Y; Yang S; Lü Z; Dong M; Zhou SY; Liu P; Zhang CG; Yang JL; Shi YK
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):385-9. PubMed ID: 22883463
[TBL] [Abstract][Full Text] [Related]
30. Prognostic impact of hepatitis C virus infection in patients with diffuse large B-cell lymphoma treated with immunochemotherapy in the context of a novel prognostic index.
Chen YY; Huang CE; Liang FW; Lu CH; Chen PT; Lee KD; Chen CC
Cancer Epidemiol; 2015 Jun; 39(3):382-7. PubMed ID: 25899771
[TBL] [Abstract][Full Text] [Related]
31. Antiviral therapy improves overall survival in hepatitis C virus-infected patients who develop diffuse large B-cell lymphoma.
Hosry J; Mahale P; Turturro F; Miranda RN; Economides MP; Granwehr BP; Torres HA
Int J Cancer; 2016 Dec; 139(11):2519-28. PubMed ID: 27501007
[TBL] [Abstract][Full Text] [Related]
32. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological features of HCV-positive splenic diffuse large B cell lymphoma.
Shimono J; Miyoshi H; Arakawa F; Yamada K; Sugio T; Miyawaki K; Eto T; Miyagishima T; Kato K; Nagafuji K; Akashi K; Teshima T; Ohshima K
Ann Hematol; 2019 May; 98(5):1197-1207. PubMed ID: 30729289
[TBL] [Abstract][Full Text] [Related]
34. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
[TBL] [Abstract][Full Text] [Related]
35. Hepatitis C infection is associated with hepatic toxicity but does not compromise the survival of patients with diffuse large B cell lymphoma treated with rituximab-based chemotherapy.
Chen TT; Chiu CF; Yang TY; Lin CC; Sargeant AM; Yeh SP; Liao YM; Bai LY
Leuk Res; 2015 Feb; 39(2):151-6. PubMed ID: 25524176
[TBL] [Abstract][Full Text] [Related]
36. Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma.
Tisi MC; Cupelli E; Santangelo R; Maiolo E; Alma E; Giachelia M; Martini M; Bellesi S; D'Alò F; Voso MT; Pompili M; Leone G; Larocca LM; Hohaus S
Leuk Lymphoma; 2016; 57(3):628-34. PubMed ID: 26458141
[TBL] [Abstract][Full Text] [Related]
37. Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy.
Arcaini L; Merli M; Volpetti S; Rattotti S; Gotti M; Zaja F
Clin Dev Immunol; 2012; 2012():638185. PubMed ID: 22956970
[TBL] [Abstract][Full Text] [Related]
38. Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.
Ok CY; Li L; Xu-Monette ZY; Visco C; Tzankov A; Manyam GC; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Chen J; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ai W; Ponzoni M; Ferreri AJ; Farnen JP; Møller MB; Bueso-Ramos CE; Miranda RN; Winter JN; Piris MA; Medeiros LJ; Young KH
Clin Cancer Res; 2014 May; 20(9):2338-49. PubMed ID: 24583797
[TBL] [Abstract][Full Text] [Related]
39. Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies.
Purdum A; Tieu R; Reddy SR; Broder MS
Oncologist; 2019 Sep; 24(9):1229-1236. PubMed ID: 30850561
[TBL] [Abstract][Full Text] [Related]
40. Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH.
Nieters A; Kallinowski B; Brennan P; Ott M; Maynadié M; Benavente Y; Foretova L; Cocco PL; Staines A; Vornanen M; Whitby D; Boffetta P; Becker N; De Sanjosé S
Gastroenterology; 2006 Dec; 131(6):1879-86. PubMed ID: 17087949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
